| アブストラクト | PURPOSE: To describe the use of antimuscarinic drugs to treat overactive bladder (OAB) in Denmark, Sweden, and the United Kingdom (UK). METHODS: We identified new users of darifenacin, fesoterodine, oxybutynin, solifenacin, tolterodine, and trospium aged 18 years or older from the Danish National Registers (2004-2012), the Swedish National Registers (2006-2012), and UK Clinical Practice Research Datalink (2004-2012). Users were followed until disenrollment, cancer diagnosis, death, or study end. Treatment episodes, identified by linking consecutive prescriptions, were described with respect to duration, drug switch, and drug add-on. RESULTS: Mean age of OAB drug users was 66 years in Denmark (n = 72,917) and Sweden (n = 130,944), and 62 years in the UK (n = 119,912); 60% of Danish and Swedish patients and 70% of UK patients were female. In Denmark, of 224,680 treatment episodes, 39% were with solifenacin, and 35% with tolterodine; 2% were with oxybutynin. In Sweden, of 240,141 therapy episodes, 37% were with tolterodine and 35% with solifenacin; 5% were with oxybutynin. In the UK, of 245,800 treatment episodes, 28% were with oxybutynin, 27% with solifenacin, and 26% with tolterodine. In the three countries, 49%-52% of treatment episodes comprised one prescription and over 80% of episodes ended because of no refill; less than 20% ended because of a switch to another antimuscarinic. During the study years, we observed a change in OAB treatment preference from tolterodine to solifenacin. CONCLUSIONS: In these cohorts, persistence with antimuscarinic drugs was low. By 2012, the preferred drug was solifenacin; oxybutynin use was marginal in Nordic countries compared with the UK. |
|---|
| ジャーナル名 | PloS one |
|---|
| Pubmed追加日 | 2018/9/28 |
|---|
| 投稿者 | Margulis, Andrea V; Linder, Marie; Arana, Alejandro; Pottegard, Anton; Berglind, Ina Anveden; Bui, Christine L; Kristiansen, Nina Sahlertz; Bahmanyar, Shahram; McQuay, Lisa J; Atsma, Willem Jan; Appenteng, Kwame; D'Silva, Milbhor; Perez-Gutthann, Susana; Hallas, Jesper |
|---|
| 組織名 | Pharmacoepidemiology and Risk Management, RTI Health Solutions, Barcelona, Spain.;Centre for Pharmacoepidemiology, Karolinska Institutet, Stockholm, Sweden.;Clinical Pharmacology and Pharmacy, Department of Public Health, University of;Southern Denmark, Odense, Denmark.;Pharmacoepidemiology and Risk Management, RTI Health Solutions, Research Triangle;Park, North Carolina, United States of America.;Astellas, Leiden, Netherlands.;Astellas, Northbrook, Illinois, United States of America. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/30260993/ |
|---|
